Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 22

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 22
---
 we raise capital through the sale of equity,
or securities convertible into equity, it will result in dilution to our then existing stockholders, which could be significant depending
on the price at which we may be able to sell our securities.

If we raise additional capital through the incurrence
of indebtedness, we may become subject to covenants restricting our business activities, and holders of debt instruments may have rights
and privileges senior to those of our equity investors. In addition, servicing the interest and principal repayment obligations under
debt facilities could divert funds that would otherwise be available to support research and development or commercialization activities.
Any debt financing that we obtain in the future could involve substantial restrictions on activities and creditors could seek a pledge
of some or all of our assets. We have not identified potential sources for such financing that we will require, and we do not have commitments
from any third parties to provide any future debt financing.

If we are unable to raise capital when needed
on commercially reasonable terms, we could be forced to delay, reduce or eliminate our research and development for our product candidates
or any future commercialization efforts or ultimately cease operations. Any of these events could significantly harm our business, financial
condition and prospects.

We anticipate that we can successfully develop the acquired business of LipoVation resulting from the closing of the Share Exchange. However, if we fail to comply with LipoVation’s contractual obligations under the Yissum License Agreements, we could lose license rights that may be necessary for developing our Nano-Liposomal Particles (NLP)-based medicines based therapeutic products.

The exclusive license granted to LipoVation by
Yissum under the Yissum License Agreements imposes various development, commercialization, funding, royalty, diligence, sublicensing,
insurance and other obligations on us. Our obligations under the Yissum License Agreements include, without limitation:

| ● | royalty payments; |

| ● | annual maintenance fees; |

<div align='center'>10</div>

| ● | annual progress reports; |

| ● | milestone payments; |

| ● | maintaining insurance coverage; |

| ● | paying fees related to prosecution, maintenance and 
 enforcement of patent rights; and                   |

| ● | undertaking diligent efforts to develop and to introduce                
 therapeutic products into the commercial market as soon as practicable. |

These obligations subject us to the risk that
we may lose such license if we breach any of our material obligations described above and fail to remedy such material breach within
90